Status:
COMPLETED
Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic
Lead Sponsor:
Centre Henri Becquerel
Conditions:
Hodgkin's Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
More than 90% of patients with Hodgkin lymphoma (HL) can recover thanks to conventional polychemotherapy regimens - ABVD or BEACOPP - with or without radiotherapy. Nevertheless, some patients relapse ...
Detailed Description
To evaluate the decrease of cytokines concentration with a prognostic value as markers of response, the dosage of TARC, IL-6, IL1-RA, sCD30 and TNFR1 will be performed during treatment at :diagnosis, ...
Eligibility Criteria
Inclusion
- Hodgkin Lymphoma diagnosis
- I-II or III-IV Stages
- untreated Patient (including corticosteroids)
- Patient treated and followed exclusively in center Henri Becquerel
- Informed Consent signed
Exclusion
- psychological, social or family conditions not allowing a suitable follow-up for study
- Mental deficiency not allowing the good understanding of study procedures
- positive HIV serology
- positive B or C Hepatitis serology
- Pregnant or lactating
- Patient registered with a social security scheme or in an equivalent situation
- Patient in a period of exclusion on another biomedical study.
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01833884
Start Date
April 1 2010
End Date
June 1 2016
Last Update
July 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Henri Becquerel
Rouen, France, 76000